London Daily

Focus on the big picture.
Thursday, Feb 06, 2025

Moderna flu vaccine delivers mixed results in trial, shares fall

Moderna flu vaccine delivers mixed results in trial, shares fall

Moderna Inc. on Thursday said its closely watched experimental messenger RNA-based influenza vaccine generated a strong immune response against A strains of the flu but failed to show it was at least as effective as an approved vaccine versus less prevalent influenza B.
The results dashed investor hopes that the company might plug its COVID franchise decline, sending Moderna’s shares down more than 6 percent in after-hours trading.

Moderna, whose only marketed product is its COVID-19 shot, has high hopes for its flu vaccine and aims to grab large portions of the respiratory syncytial virus (RSV) and seasonal flu markets with new mRNA vaccines.

The company said its vaccine, called mRNA-1010, generated a stronger immune response for the A/H3N2 and A/H1N1 strains than the marketed vaccine it was tested against in a trial of 6,102 adults aged 18 and over across Argentina, Australia, Colombia, Panama and the Philippines during flu season there.

It failed to meet its goal of non-inferiority compared to the conventional vaccine for the B/Victoria and B/Yamagata-lineage strains, the drugmaker said.

Cowen analyst Tyler Van Buren said investors had hoped Moderna would replace its COVID revenue with RSV and flu vaccine income, especially after it delivered positive RSV vaccine efficacy results in January.

“But to fill that big COVID decline, you need RSV and flu. The efficacy results could tell a different story when they come out, but there was no doubt that the most recent vaccine data was a mixed bag,” he said.

He said physicians and patients might be put off by Moderna’s flu vaccine’s results for Influenza B and the high rate of side effects.

The US company said it has already updated mRNA-1010 in a way it believes will improve immune responses against Influenza B and will test those changes.

“We have always said our goal is to produce a flu vaccine, and then to iterate it, and to fine tune it over time to really make it exceptional,” Chief Medical Officer Paul Burton said in an interview.

Dr. David Boulware, an infectious disease specialist at the University of Minnesota Medical School, said he was not overly concerned about the immune response versus Influenza B.

Boulware said the immune response against the A strains demonstrated that the vaccine probably worked and Moderna’s tweaks to the vaccine are likely to improve the response against the B strains.

“I consider it pretty positive,” he said.

Seventy percent of those who received Moderna’s shot reported mostly mild adverse reactions compared to 48 percent for the conventional flu vaccine. Pain and swelling at the injection site as well as headaches and fatigue were among the most commonly reported side effects.

The company also has an ongoing late-stage efficacy study on the mRNA-1010 flu vaccine, which could have data within weeks.

If that trial reads out soon, Burton said he hopes to have the data prepared and sent to regulators in the first half of this year, which could allow them to review it as soon as late 2023 or early 2024.

The flu, an infection of the nose, throat and lungs, kills 290,000 to 650,000 people worldwide annually.
Newsletter

Related Articles

0:00
0:00
Close
Trump Signs Executive Order Prohibiting Transgender Athletes from Competing in Women's Sports
Intense Pressure Builds for a Free Trade Agreement Between the UK and GCC in Light of Economic Difficulties
UAE Aids in the Transfer of 300 Prisoners Between Russia and Ukraine.
Trump Suggests U.S. 'Takeover' of Gaza, Sparking Global Worries
At least ten fatalities reported in Swedish school shooting, authorities confirm.
EU Reveals Significant Advances on Special Tribunal for Prosecuting Vladimir Putin
Trump Administration Preparing Executive Order to Abolish the Department of Education
Trump's Gaza Plan Provokes Global Debate
Spain Endorses Initiative to Cut Working Week to 37.5 Hours
Australia Prohibits DeepSeek AI on Government Devices Due to Security Issues
Trump Warns of Tariffs on EU Products, Labels Bloc an 'Atrocity' in Trade Matters
Zelenskyy Proposes Nuclear Arsenal if NATO Membership Lingers.
Zelenskyy Urges for 'Robust Security Assurances' from Russia to Conclude the Conflict in Ukraine
European Union Proposes Reforms to 1951 Refugee Convention
China's humanoid robots poised to transform everyday living and spiritual functions.
Changes in US tariffs on Chinese products could affect consumers more significantly than they do China.
How Innovations in China's Humanoid Robots Ignite Fierce Competition with the US
Germany Experiences 34% Decrease in Asylum Applications During Migration Discussion
Experts Challenge Conviction of UK Nurse Lucy Letby for Baby Killings
AfD Chief Alice Weidel Enhances Global Standing Through Meeting with Viktor Orban
Nigel Farage's Reform UK Party Leads Poll Amid Growing Public Demand for Change
Conor Murphy Steps Down as Northern Ireland Economy Minister to Join Irish Parliament
Over 1 Million Face Penalties After Missing HMRC Self-Assessment Tax Deadline
Scottish Government Denies Plans to Ban Cat Ownership Amid Controversy
Bridget Phillipson Urges Parents to Prioritize School Attendance Amid Rising Absence Rates
Keir Starmer Advocates for Stronger UK-EU Security Partnership in Brussels
Six English Councils Granted Permission to Raise Council Tax Bills Above Cap Amid Financial Struggles
Keir Starmer Faces Growing Backlash Over Potential Approval of Rosebank Oilfield
AI Consciousness Raises Ethical Concerns, Say Experts
Families Urge NHS England to Release Full Report on Nottingham Triple Homicide
NHS Initiates Largest AI Trial for Breast Cancer Detection
UK Tightens Regulations on Online Sales of Weight-Loss Injections
Gambling Ads Shown to Parents on Baby Monitor App, Raising Concerns
Ancient Irish Rainforests at Risk Due to the Growth of Monoculture Plantations
EU Leaders Deliberate on Defense Strategy Amid Rising U.S. Tensions
EU Leaders Convene Important Summit on Defense in Response to Rising Tensions
Trump Directs Establishment of U.S. Sovereign Wealth Fund, Considers TikTok Purchase
Britain Considers U.S. Gas Imports in Response to Possible Trump Tariffs
French Prime Minister Bayrou Confronts Several No-Confidence Votes Regarding the 2025 Budget
Shutdown of USAID Headquarters in Light of U.S. Government Reduction Initiatives
President Trump Launches Establishment of U.S. Sovereign Wealth Fund with Possible TikTok Purchase
Investigation Launched Following Viral Video of Bodybuilder's Airport Prank
Cooling Blankets: A Remedy for Those Who Sleep Hot or Just a Marketing Ploy?
Trump Wins Again as Canada Agrees to Strengthen Border Security
Trump Seeks Rare Minerals from Ukraine in Exchange for U.S. Support
EU Leaders Reach Consensus to Increase Defence Expenditure in Response to Growing Security Threats
UK Business Confidence Declines Amid Economic Uncertainty, Lloyds Survey Shows
Abhishek Sharma's Century Secures India a 4-1 T20 Series Win Over England
UK Prime Minister Keir Starmer will welcome German Chancellor Olaf Scholz for talks at Chequers.
Australian soccer sensation Sam Kerr confronts a racial abuse trial in London.
×